Expert Review of Endocrinology & Metabolism最新文献_第3页

Current perspectives on metformin administration during pregnancy. 妊娠期间二甲双胍给药的现状。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-05-01 Epub Date: 2026-04-19 DOI: 10.1080/17446651.2026.2661931

Panagiotis Peitsidis

引用次数: 0

Bridging the diagnostic gap: coronary calcium and osteoporosis. 弥合诊断差距：冠状动脉钙和骨质疏松症。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-04 DOI: 10.1080/17446651.2026.2635525

Suvasini Lakshmanan, Matthew Budoff

{"title":"Bridging the diagnostic gap: coronary calcium and osteoporosis.","authors":"Suvasini Lakshmanan, Matthew Budoff","doi":"10.1080/17446651.2026.2635525","DOIUrl":"https://doi.org/10.1080/17446651.2026.2635525","url":null,"abstract":"Introduction: Subclinical atherosclerosis measured by coronary artery calcium (CAC) and osteoporosis often co-exist as indolent 'silent' conditions, remain underdiagnosed and undertreated, and are associated with significant morbidity and mortality. Bone density can be obtained accurately from non-contrast CAC scans, allowing for 'opportunistic' screening of OP without the need for additional tests or radiation, and thereby enhancing the yield of CAC scans and improving patient care globally.Areas covered: This review will seek to highlight the significant relationship between osteoporosis and sub- clinical atherosclerosis. We also highlight the role of opportunistic measurements of bone mineral density (BMD) to accurately detect osteoporosis and osteopenia in CAC scans, without the need for additional radiation, tests, or financial burden.Expert opinion: Osteoporosis is a major health problem, associated with significant morbidity and mortality, yet the condition remains under recognized, under diagnosed and undertreated. CT measurement of bone density is likely superior to BMD measures by DEXA, for fracture prediction. A link between CAC and osteoporosis beyond aging alone highlights the potential role of 'opportunistic screening' by non-enhanced CAC scans for early detection of osteoporosis and subclinical atherosclerosis simultaneously.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"1-7"},"PeriodicalIF":2.8,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oral GLP-1 receptor agonists for the treatment of obesity: ATTAINing metabolic benefits to find the OASIS. 口服GLP-1受体激动剂治疗肥胖：获得代谢益处以发现OASIS。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-01 Epub Date: 2026-02-25 DOI: 10.1080/17446651.2026.2634086

Kyriaki Vafeidou, Theocharis Koufakis, Konstantinos Stavropoulos, Maria Zarfeiadou, Michael Doumas, Dimitrios Patoulias

引用次数: 0

Is there anything left to eat? A lived experience insight of following a restrictive type 1 diabetes and dialysis diet. 还有什么可吃的吗？1型糖尿病和透析饮食后的生活经验。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-01 Epub Date: 2025-01-29 DOI: 10.1080/17446651.2025.2454396

Suzanne Schneider, Thomas M Barber, Marcus Saemann, Joanna Thurston

{"title":"Is there anything left to eat? A lived experience insight of following a restrictive type 1 diabetes and dialysis diet.","authors":"Suzanne Schneider, Thomas M Barber, Marcus Saemann, Joanna Thurston","doi":"10.1080/17446651.2025.2454396","DOIUrl":"10.1080/17446651.2025.2454396","url":null,"abstract":"Objectives: Chronic kidney disease has a global morbidity burden of >10%, with diabetes being a major cause. Nutrition therapy is vital in managing both chronic conditions, yet CKD dietary guidelines contradict healthy eating advice, and can result in major psychological and social burdens. Few studies investigate the patient's experience of being placed on such a restrictive diet. This auto/biographical review provides a unique perspective and aims to assist practitioners as they guide patients on 'what is left to eat.'Method: An auto/biographical approach, supported by a comprehensive literature review using data from MEDLINE, Embase, and PsychoINFO, was used to answer the question: 'What are the diet and lifestyle challenges of following a restrictive Type 1 Diabetes/CKD dialysis diet?'Results: Restrictive dietary and fluid regimes have a major effect on patients' illness beliefs, anxieties, and independence. This is discussed through five themes: Food is belonging; Normal is a Fallacy; Your numbers define you; A disease disguised as a virtue and Meeting the Elephant: ESKD diagnosis and the burden of dialysis.Conclusion: Dietary intervention is crucial in the management of T1D and ESKD, but equally important is to consider the implications of strict dietary regimes without sufficient evidence, guidance, and support.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"153-166"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143064455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to treat diabetes mellitus in the older patients: being risk averse versus being too progressive. 如何治疗老年糖尿病患者：规避风险vs过于进步。

IF 2.8

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-01 Epub Date: 2026-02-22 DOI: 10.1080/17446651.2026.2632022

Sandeep Singh, Jeske J Walgers, Suat Simsek, René W M M Jansen, Majon Muller, Max Nieuwdorp, Sara-Joan Pinto-Sietsma

引用次数: 0

Skin deep: dermatologic challenges in PCOS through the female lifespan. 皮肤深层：女性一生中多囊卵巢综合征的皮肤病挑战。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-01 Epub Date: 2026-02-19 DOI: 10.1080/17446651.2026.2632020

Seda Hanife Oğuz, Başak Yalici Armagan, Bulent Okan Yildiz

{"title":"Skin deep: dermatologic challenges in PCOS through the female lifespan.","authors":"Seda Hanife Oğuz, Başak Yalici Armagan, Bulent Okan Yildiz","doi":"10.1080/17446651.2026.2632020","DOIUrl":"10.1080/17446651.2026.2632020","url":null,"abstract":"Introduction: Polycystic ovary syndrome (PCOS) is a lifelong endocrine-metabolic condition with prominent dermatologic manifestations such as hirsutism, acne/seborrhea, and female pattern hair loss (FPHL), which are frequently the initial complaint for seeking medical attention.Areas covered: This review explores the pathogenesis and dermatologic presentation of PCOS across the lifespan, emphasizing evidence-based diagnostic strategies, based on a PubMed literature search through August 2025. It also highlights the impact on quality of life, the need for psychosocial support, and the importance of cultural sensitivity in care. Management approaches are reviewed including pharmacologic therapies, procedures, and considerations across reproductive stages including pregnancy, postpartum, and menopause. Future directions in management are also discussed.Expert opinion: Current care remains largely symptom-driven. A shift toward mechanism-based, personalized therapy is essential. Key priorities include biomarker-guided treatment, standardized assessment tools, cautious antibiotic use with microbiome-sparing approaches, and clinical trials targeting treatment-resistant/recurrent cases and FPHL. In the future, routine care should incorporate phenotype- and biomarker-based algorithms, artificial intelligence (AI)-assisted assessment, and integrated mental health support.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"123-142"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Osilodrostat for the treatment of Cushing syndrome: an update. 奥西洛司他治疗库欣综合征的最新进展。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-01 Epub Date: 2026-02-20 DOI: 10.1080/17446651.2026.2615346

Lukasz Dzialach, Przemyslaw Witek

引用次数: 0

The role of batokines in metabolism and their therapeutic potential. 细胞因子在代谢中的作用及其治疗潜力。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-01 Epub Date: 2026-02-03 DOI: 10.1080/17446651.2026.2624400

Hossein Mirmiranpour, Thomas M Barber

{"title":"The role of batokines in metabolism and their therapeutic potential.","authors":"Hossein Mirmiranpour, Thomas M Barber","doi":"10.1080/17446651.2026.2624400","DOIUrl":"10.1080/17446651.2026.2624400","url":null,"abstract":"Introduction: Interlinkage between lipid and carbohydrate metabolism remains a key focus of research into the pathogenesis and novel management of obesity-related conditions like Type 2 Diabetes (T2DM), dyslipidaemia, and Metabolic-Associated Fatty Liver Disease (MAFLD). The activity of Brown Adipose Tissue (BAT) unifies these two facets of metabolism and holds great therapeutic potential.Areas covered: Through a brief narrative review of the current literature using Pubmed, with the search terms 'batokines,' 'metabolism' and 'obesity,' we outline the diverse effects of batokines on metabolism, BAT functioning, and metabolic signaling pathways. We explore a future role of batokines in the management of obesity and T2DM, as a biomarker for BAT activity and predictor and monitor of therapeutic response to future novel mitochondrial uncoupling therapies.Expert opinion: Through its key role in the metabolism of lipids and carbohydrates, the mechanisms of BAT activation shed light on the complex mechanisms that interlink obesity with T2DM and other dysmetabolic conditions. Signaling biomolecules derived from BAT ('batokines') regulate the metabolic functioning of white adipose tissue and skeletal muscle, including glucose, lipid and protein metabolism, insulin sensitivity, and energy expenditure. Insights into batokine physiology will guide the next generation of therapies for obesity and its related dysmetabolic conditions.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"143-151"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dialysis meets devices: the use of automated insulin delivery in end stage kidney disease and haemodialysis. 透析满足设备：终末期肾脏疾病和血液透析中自动胰岛素输送的使用。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-03-01 Epub Date: 2026-02-02 DOI: 10.1080/17446651.2026.2619097

Panagiotis Pavlou, Lalantha Leelarathna, Parizad Avari, Sufyan Hussain, Thomas Johnston, Rebecca Hyslop, Siobhan Pender, Janaka Karalliedde

{"title":"Dialysis meets devices: the use of automated insulin delivery in end stage kidney disease and haemodialysis.","authors":"Panagiotis Pavlou, Lalantha Leelarathna, Parizad Avari, Sufyan Hussain, Thomas Johnston, Rebecca Hyslop, Siobhan Pender, Janaka Karalliedde","doi":"10.1080/17446651.2026.2619097","DOIUrl":"10.1080/17446651.2026.2619097","url":null,"abstract":"Introduction: Diabetes management in end-stage kidney disease (ESKD) presents unique challenges due to perturbations in renal physiology. ESKD influences the pharmacokinetics of insulin and glucose metabolism, while hemodialysis (HD) adds further complexity. There is an unmet need for adaptable therapies to help glucose management in ESKD. Automated insulin delivery (AID) may provide a solution to the dynamic, complex physiology of diabetes in ESKD on HD.Areas covered: We provide a narrative review of the pathophysiology of diabetes in ESKD on HD and the role of AID in this setting. Literature search included PubMed/MEDLINE and Scopus. We included manuscripts published between 2000 and 2025 focussed on the pathophysiology of diabetes in people with ESKD on HD and 2015 to 2025 for AID use in the setting of ESKD on HD.Expert opinion: Our review of the pathophysiology of diabetes in ESKD on HD and the utilization of AID in this setting highlights the need for further research to establish the evidence base for this technology in this high-risk population. The available data support the use of AID systems as they provide greater flexibility in insulin delivery, increase time within target range (3.9-10 mmol/L), and reduce glycemic variability and hypoglycemia, thus emerging as a promising treatment modality in people with insulin-treated diabetes and ESKD on HD.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"111-121"},"PeriodicalIF":2.9,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of sexual dysfunction in menopause: an update on evidence-based strategies. 更年期性功能障碍的管理：循证策略的最新进展。

IF 2.9

Expert Review of Endocrinology & Metabolism Pub Date : 2026-01-01 Epub Date: 2025-11-07 DOI: 10.1080/17446651.2025.2585855

Giorgia E Parrotta, Laura Cucinella, Rossella E Nappi

{"title":"Management of sexual dysfunction in menopause: an update on evidence-based strategies.","authors":"Giorgia E Parrotta, Laura Cucinella, Rossella E Nappi","doi":"10.1080/17446651.2025.2585855","DOIUrl":"10.1080/17446651.2025.2585855","url":null,"abstract":"Introduction: Female sexual dysfunction (FSD) at menopause is a group of prevalent and multifactorial conditions that significantly impair quality of life and well-being. Hormonal decline, particularly estrogen and androgen deprivation, along with aging-related changes, contribute to genitourinary syndrome of menopause (GSM) and hypoactive sexual desire disorder (HSDD), the two most relevant clinical entities.Areas covered: This narrative review provides an updated revision of the literature regarding evidence-based strategies for FSD in menopausal women. Emphasis is placed on pharmacologic treatments, including systemic and local hormonal and non-hormonal therapies, selective estrogen receptor modulators (SERM), and centrally acting agents. Non-pharmacological interventions are also discussed, such as pelvic floor rehabilitation, laser therapies, and psychosexual approaches (cognitive behavioral therapy, mindfulness, couple therapy). The content draws mainly on recent clinical trials, consensus statements, and guideline-based recommendations, based on Pubmed search updated to July 2025.Expert opinion: Management of FSD associated with menopause requires a multidimensional, individualized approach integrating biological, psychological, and relational factors. A proactive and structured clinical framework, supported by validated diagnostic tools, is essential. Healthcare providers (HCPs) should address sexual health openly, recognize the couple's dynamics, and tailor interventions to each woman's needs and preferences, while considering the evolving evidence and regulatory landscape.","PeriodicalId":12107,"journal":{"name":"Expert Review of Endocrinology & Metabolism","volume":" ","pages":"13-27"},"PeriodicalIF":2.9,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145458017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0